Adage Capital Partners
HRTX icon

Adage Capital Partners’s Heron Therapeutics HRTX Stock Holding History

Adage Capital Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,185,325
Closed -$14.5M – 1013
2025
Q4 		$14.5M Buy
11,185,325
+946,100
+9% +$1.17M 0.02% 585
2025
Q3 		$12.9M Buy
10,239,225
+2,387,225
+30% +$3.78M 0.02% 583
2025
Q2 		$16.3M Hold
7,852,000
– – 0.03% 492
2025
Q1 		$17.3M Sell
7,852,000
-648,000
-8% -$1.26M 0.03% 455
2024
Q4 		$13M Sell
8,500,000
-350,000
-4% -$567K 0.02% 544
2024
Q3 		$17.6M Buy
8,850,000
+1,250,000
+16% +$2.98M 0.03% 482
2024
Q2 		$26.6M Buy
7,600,000
+4,689,989
+161% +$14.4M 0.05% 364
2024
Q1 		$8.06M Hold
2,910,011
– – 0.02% 637
2023
Q4 		$4.95M Buy
2,910,011
+910,011
+46% +$1M 0.01% 686
2023
Q3 		$2.06M Buy
2,000,000
+1,000,000
+100% +$1.42M ﹤0.01% 736
2023
Q2 		$1.16M Buy
+1,000,000
New +$1.78M ﹤0.01% 764
2015
Q4 		– Sell
-114,700
Closed -$2.8M – 715
2015
Q3 		$2.8M Buy
+114,700
New +$3.82M 0.01% 659

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Adage Capital Partners's HRTX Position: Q1 2026 in Review

Adage Capital Partners sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 11,185,325 shares — an estimated $14.5M sold.

Adage Capital Partners first reported a position in HRTX in Q3 2015 and held it in 12 quarters. The position peaked at $26.6M in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Adage Capital Partners reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Adage Capital Partners sold 11,185,325 Heron Therapeutics shares in Q1 2026, an estimated $14.5M.
  • Adage Capital Partners first reported a position in Heron Therapeutics in Q3 2015 and held it in 12 quarters.
  • Adage Capital Partners's Heron Therapeutics position peaked at $26.6M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.